erlotinib hydrochloride has been researched along with oxadiazoles in 2 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (oxadiazoles) | Trials (oxadiazoles) | Recent Studies (post-2010) (oxadiazoles) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 6,057 | 257 | 2,359 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dittmann, K; Fehrenbacher, B; Huber, S; Mayer, C; Paasch, A; Rodemann, HP; Schaller, M | 1 |
| Gomaa, HAM; Mahmoud, MA; Mohammed, AF; Salem, OIA; Youssif, BGM | 1 |
2 other study(ies) available for erlotinib hydrochloride and oxadiazoles
| Article | Year |
|---|---|
Nuclear EGFR renders cells radio-resistant by binding mRNA species and triggering a metabolic switch to increase lactate production.
Topics: Blotting, Western; Bronchial Neoplasms; Cell Line, Tumor; Cell Nucleus; Dasatinib; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression; Head and Neck Neoplasms; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Lactic Acid; Nuclear Proteins; Oxadiazoles; Protein Kinase Inhibitors; Pyrazoles; Radiation Tolerance; RNA, Messenger | 2015 |
New 1,3,4-oxadiazoles linked with the 1,2,3-triazole moiety as antiproliferative agents targeting the EGFR tyrosine kinase.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Doxorubicin; Drug Screening Assays, Antitumor; ErbB Receptors; Erlotinib Hydrochloride; Humans; Molecular Structure; Oxadiazoles; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Structure-Activity Relationship; Triazoles | 2022 |